Low-dose LPS promotes progress of non-alcoholic steatohepatitis by up-regulating TLR4 in macrophages
Basic Medicine|更新时间:2026-01-09
|
Low-dose LPS promotes progress of non-alcoholic steatohepatitis by up-regulating TLR4 in macrophages
Journal of Third Military Medical UniversityVol. 43, Issue 22, Pages: 2423-2434(2021)
作者机构:
1.261053 山东 潍坊,潍坊医学院山东省高校免疫学重点实验室
2.61053 山东 潍坊,潍坊医学院免疫学教研室
3.61053 山东 潍坊,潍坊医学院病原微生物教研室
4.61053 山东 潍坊,潍坊医学院第一附属医院内分泌科
作者简介:
基金信息:
the General Program of National Natural Science Foundation of China(81873883);the National Natural Science Foundation for Young Scholars of China(82000525);the Project of Medical Science and Technology Development Plan of Shandong Province(2018WS065);the Project of Science and Technology Development Plan of Weifang City(2020YX011)
Yang YU, Xiaoyan FU, Yanhong WU, et al. Low-dose LPS promotes progress of non-alcoholic steatohepatitis by up-regulating TLR4 in macrophages[J]. Journal of Third Military Medical University, 2021, 43(22): 2423-2434.
DOI:
Yang YU, Xiaoyan FU, Yanhong WU, et al. Low-dose LPS promotes progress of non-alcoholic steatohepatitis by up-regulating TLR4 in macrophages[J]. Journal of Third Military Medical University, 2021, 43(22): 2423-2434. DOI: 10.16016/j.1000-5404.202105117.
Low-dose LPS promotes progress of non-alcoholic steatohepatitis by up-regulating TLR4 in macrophages
To investigate the role and underlying mechanisms of lipopolysaccharide (LPS) in the promotion of non-alcoholic steatohepatitis.
Methods
2
Wild type B6 (B6.WT) mice aged 6~8 weeks were randomly divided into 3 groups and fed with normal diet (ND)
high-fat diet (HFD) and HFD combined LPS injection (HFD+LPS)
respectively. LPS (0111∶B4
1.25 μg/g body weight) was injected intraperitoneally to the mice of the HFD+LPS group once a week
and normal saline of same amount was given to the mice of the other 2 groups. After 10 weeks' feeding
the levels of triglycerides (TG)
total cholesterol (TC)
alanine aminotransferase (ALT) and aspartate transaminase (AST) in the serum and liver tissue were detected by enzyme based assays. The lipid deposition in the liver was observed by oil red O staining. The levels of IL-1β
TNF-α
CCL5
CCL2 and CCL4 in the serum and liver tissue were measured by ELISA. The mRNA levels of IL-1β
TNF-α
CCL5
CCL2 and CCL4 in the liver tissue were detected by quantitative real time-PCR (RT-qPCR). The pathological changes of liver tissue and inflammatory cell infiltration were detected by HE staining. Infiltration of macrophages and neutrophils
and the expression of TLR4 in the liver tissue was analyzed by immunofluorescence (IF) assay. Proportion of macrophages and neutrophils in the liver was assessed by flow cytometry.
Results
2
The serum levels of TG and TC were significantly higher in the HFD group than the ND group (
P
<
0.05). Their contents in the liver were markedly increased in the HFD+LPS group than the HFD group (
P
<
0.01). The mice from the HFD+LPS group had more obvious vacuolar degeneration of liver cells
infiltration of inflammatory cells
higher NAS score (
P
<
0.05) and larger number of infiltrated mononuclear cells (
P
<
0.01) when compared with the HFD group. IF assay and flow cytometry proved that HFD+LPS treatment induced significantly obvious infiltration of hepatic macrophages and neutrophil accumulation (
P
<
0.05). ELISA proved that HFD+LPS treatment increased serum levels of IL-1β
TNF-α
CCL5 and CCL2 (
P
<
0.05)
elevated mRNA levels of IL-1β
CCL5 and CCL2 in the liver tissue (
P
<
0.05). IF revealed that TLR4 showed obvious cell membrane translocation in liver tissue after LPS treatment
and the co localization of TLR4 and macrophages showed that the expression of TLR4 on the surface of macrophages in HFD + LPS group was significantly higher than that in HFD group(
P
<
0.01).
Conclusion
2
LPS mediates intrahepatic infiltration of macrophages and neutrophils and aggravates the process of NASH in mice fed with HFD through upregulating TLR4 expression on macrophages to induce chemokines and inflammatory cytokines.
关键词
Keywords
references
FRIEDMAN S L, NEUSCHWANDER-TETRI B A, RINELLA M, et al . Mechanisms of NAFLD development and therapeutic strategies. Nat Med, 2018, 24(7): 908-922. DOI: 10.1038/s41591-018-0104-9.
RINELLA M E. Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, 313(22): 2263-2273. DOI: 10.1001/jama.2015.5370.
YOUNOSSI Z, ANSTEE Q M, MARIETTI M, et al . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20. DOI: 10.1038/nrgastro.2017.109.
YEH C F, CHEN Y H, LIU S F, et al . Mutual interplay of host immune system and gut microbiota in the immunopathology of atherosclerosis. Int J Mol Sci, 2020, 21(22): E8729. DOI: 10.3390/ijms21228729.
RATZIU V, HARRISON S A, FRANCQUE S, et al . Elafibranor, an agonist of the peroxisome proliferator-ac tivated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology, 2016, 150(5): 1147-1159. e5. DOI: 10.1053/j.gastro.2016.01.038.
WIGG A J, ROBERTS-THOMSON I C, DYMOCK R B, et al . The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut, 2001, 48(2): 206-211. DOI: 10.1136/gut.48.2.206.
JINDAL A, BRUZZÌ S, SUTTI S, et al . Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH). Exp Mol Pathol, 2015, 99(1): 155-162. DOI: 10.1016/j.yexmp.2015.06.015.
National Group on Fatty Liver and Alcoholic Liver Disease of Chinese Society of Hepatology of Chinese Medical Association, Fatty Liver Expert Committee of Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
BAECK C, WEI X, BARTNECK M, et al . Pharmacological inhibiti on of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration inmice. Hepatology, 2014, 59(3): 1060-1072. DOI: 10.1002/hep.26783.
WU J P, XIAO H Y, ZHENG X L, et al . Expression and significance of interleukin 25 and its related factors in serum and liver of patients with non-alcoholic fatty liver. J Third Mil Med Univ, 2021, 43(01): 83-90. DOI: 10.16016/j.1000-5404.202005286.
WESOLOWSKI S R, KASMI K C, JONSCHER K R, et al . Developmental origins of NAFLD: a womb with a clue. Nat Rev Gastroenterol Hepatol, 2017, 14(2): 81-96. DOI: 10.1038/nrgastro.2016.160.
GRAVES D T, JIANG Y. Chemokines, a family of chemotactic cytokines. Crit Rev Oral Biol Med, 1995, 6(2): 109-118. DOI: 10.1177/10454411950060020101.
MARRA F, TACKE F. Roles for chemokines in liver disease. Gastroenterology, 2014, 147(3): 577-594. e1. DOI: 10.1053/j.gastro.2014.06.043.
PAN X F, CHIWANDA KAMINGA A, LIU A Z, et al . Chemokines in non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Front Immunol, 2020, 11: 1802. DOI: 10.3389/fimmu.2020.01802.
MIURA K, YANG L, VAN ROOIJEN N, et al . Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol, 2012, 302(11): G1310-G1321. DOI: 10.1152/ajpgi.00365.2011.
LI B H, HE F P, YANG X, et al . Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress. Transl Res, 2017, 180: 103-117. e4. DOI: 10.1016/j.trsl.2016.08.006.
BESSONE F, RAZORI M V, ROMA M G. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci, 2019, 76(1): 99-128. DOI: 10.1007/s00018-018-2947-0.
LIU Y, WU H, GONG J P, et al . Inhibition of TIM-4 in Kupffer cells alleviates hepatic ischemia-reperfusion injury in mice. J Third Mil Med Univ, 2019, 041(001): 48-55. DOI: 10.16 016/j.1000-5404.201806145.
CARPINO G, DEL BEN M, PASTORI D, et al . Increased liver localization of lipopolysaccharides in human and experimental NAFLD. Hepatology, 2020, 72(2): 470-485. DOI: 10.1002/hep.31056.
PKCδ silencing suppresses endoplasmic reticulum stress and attenuates fatty degeneration in steatotic L02 hepatocytes
Related Author
SONG Binyu
HAO Jing
LU Chengbo
LIU Yiyan
ZHANG Yitao
WEI Yuyang
XU Benjin
FU Hui
Related Institution
Department of Laboratory Medicine, Shanxi University of Medicine, Fenyang
Science and Technology Center, Shanxi University of Medicine, Fenyang
State Key Laboratory of Trauma, Burns and Combined Injury, Medical Center of Hematology, PLA Center for Hematology, Second Affiliated Hospital, Army Medical University (Third Military Medical University)
Department of Clinical Laboratory, the Second Affiliated Hospital of Zunyi Medical University
Department of Cell Biology, College of Basic Medical Sciences, Army Medical University (Third Military Medical University)